In the study, of the 76 patients treated with the PD-1 inhibitor pembrolizumab, an objective response rate of 22% was noted in the UPS subgroup, while no responses were seen in any of the other sarcoma subtypes studied. This evidence concerns the gene PDCD1 and sarcoma.